From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery
Presentations
This is some text inside of a div block.
October 28, 2025
Related announcements
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress
